Charles River Laboratories International (NYSE:CRL) Stock Price Target Raised at Mizuho

Key Points

• Mizuho raised Charles River Laboratories’ price target from $264 to $295 while maintaining a neutral rating; the new target implies roughly 0.1% downside from the stock’s $295.30 price.
• Analyst sentiment remains broadly positive, with 11 Buy, three Hold and one Sell rating, producing a “Moderate Buy” consensus and an average price target of $280.31.
• Charles River exceeded quarterly earnings expectations, reporting $3.02 in EPS versus the $2.77 consensus and $1.0 billion in revenue, though revenue declined 2.7% year over year. Insiders sold approximately $42.6 million of stock over the past three months.

Charles River Laboratories International (NYSE:CRL - Get Free Report) had its price objective hoisted by Mizuho from $264.00 to $295.00 in a report issued on Friday, Benzinga reports. The brokerage presently has a "neutral" rating on the medical research company's stock. Mizuho's price objective indicates a potential downside of 0.10% from the stock's current price.

A number of other equities analysts have also weighed in on the company. Morgan Stanley upped their target price on Charles River Laboratories International from $260.00 to $300.00 and gave the stock an "overweight" rating in a research note on Friday, August 7th. CLSA lowered Charles River Laboratories International from an "outperform" rating to a "hold" rating and set a $219.00 price objective for the company. in a report on Monday, July 20th. Weiss Ratings raised Charles River Laboratories International from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, July 1st. Piper Sandler set a $300.00 price objective on shares of Charles River Laboratories International in a research report on Monday, August 10th. Finally, Barclays reaffirmed an "overweight" rating and issued a $330.00 target price on shares of Charles River Laboratories International in a research note on Friday. Eleven analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $280.31.

Charles River Laboratories International Stock Up 6.5%

Shares of NYSE:CRL opened at $295.30 on Friday. The firm has a fifty day moving average price of $269.08 and a two-hundred day moving average price of $212.48. The company has a market cap of $14.10 billion, a price-to-earnings ratio of -60.89, a PEG ratio of 2.80 and a beta of 1.40. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. Charles River Laboratories International has a one year low of $144.26 and a one year high of $303.30.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.25. The firm had revenue of $1 billion for the quarter, compared to analysts' expectations of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The business's quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Analysts anticipate that Charles River Laboratories International will post 11.33 EPS for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In related news, CEO Birgit Girshick sold 6,500 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total value of $1,819,350.00. Following the completion of the sale, the chief executive officer owned 36,013 shares in the company, valued at $10,080,038.70. The trade was a 15.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon M. Parisotto sold 5,046 shares of the company's stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $263.00, for a total value of $1,327,098.00. Following the completion of the sale, the executive vice president directly owned 4,807 shares of the company's stock, valued at approximately $1,264,241. This represents a 51.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 165,990 shares of company stock worth $42,606,388. Company insiders own 1.30% of the company's stock.

Institutional Investors Weigh In On Charles River Laboratories International

A number of hedge funds have recently made changes to their positions in the business. Amundi increased its position in Charles River Laboratories International by 175.2% during the 1st quarter. Amundi now owns 773,315 shares of the medical research company's stock valued at $133,397,000 after purchasing an additional 492,301 shares during the period. Norges Bank bought a new position in Charles River Laboratories International in the 4th quarter worth $96,765,000. Dimensional Fund Advisors LP lifted its position in shares of Charles River Laboratories International by 14.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company's stock worth $285,001,000 after purchasing an additional 210,260 shares during the period. Empyrean Capital Partners LP bought a new stake in shares of Charles River Laboratories International during the 4th quarter valued at about $24,237,000. Finally, Clearbridge Investments LLC increased its position in shares of Charles River Laboratories International by 23.0% during the fourth quarter. Clearbridge Investments LLC now owns 511,618 shares of the medical research company's stock valued at $102,058,000 after buying an additional 95,619 shares during the period. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International News Roundup

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: 2026 earnings outlook improved: Charles River issued EPS guidance of approximately $11.45, above the analyst consensus estimate of $11.33 and at the high end of its previously stated range. Revenue guidance of about $3.9 billion was maintained and is broadly in line with expectations. Charles River Laboratories Reaffirms Fiscal 2026 Guidance; Issues 2030 Growth Projections
• Positive Sentiment: 2030 growth targets added a longer-term catalyst: Management outlined its 2030 growth projections, which investors viewed as evidence that Charles River can expand earnings and revenue beyond the current year. The company’s outlook helped drive the stock higher and places more emphasis on execution across its research and laboratory services businesses. Charles River Laboratories Stock Rises After Unveiling 2030 Growth Targets
• Neutral Sentiment: Investor focus shifts to execution: The Investor Day presentation and transcript provided additional detail on the company’s strategy and outlook, but the long-term targets remain dependent on sustained demand, operational improvement and successful execution. Revenue expectations for 2026 were not materially above consensus. Charles River Laboratories Analyst and Investor Day Transcript

About Charles River Laboratories International

Charles River Laboratories International, Inc is a global provider of drug discovery, nonclinical development and laboratory services for pharmaceutical, biotechnology and medical device companies, as well as academic and government research institutions. The company supports customers throughout the development process, from early-stage research and target identification through preclinical testing and regulatory preparation.

Its offerings include research models and related products, discovery and development services, toxicology and safety assessment, efficacy testing, bioanalysis, and laboratory testing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.